Commercialising a Regenerative Medicine Product

Commercialising a Regenerative Medicine Product

A leading university research group asked our medical device consultants to help them plan the commercialisation of a novel regenerative medicine technology designed to replace corneal transplants.

A leading university research group was at a relatively early pre-clinical research stage of developing a regenerative medicine technology that had huge potential to replace corneal transplants to treat certain eye diseases that are becoming increasingly prevalent as populations age in the developed world. The client was seeking the means for funding further development of the technology and asked us to: assess the global market opportunity; sketch out the development path through to market including the regulatory processes and likely clinical trial requirement in both the USA and Europe; consider different business models that included both autologous and allogeneic products, and central versus hub and spoke service models; obtain clinicians’ views on the different product options; consider adjacent sectors such wound care in order to supplement scarce information on the use of this type of product to treat eye diseases. Our report is currently being used to raise funding to progress the project.

We are a specialist medical device consultancy consisting of industry experts with long and successful track records in commercialising medical device products. We have broad functional and sector experience, and would welcome an opportunity to discuss with you any challenge relating to creating sustainable value from medical technologies.